Showing 26 of 26on this page. Filters & sort apply to loaded results; URL updates for sharing.26 of 26 on this page
🔥 Can chemo-free IO + DLL3 targeting redefine 1L ES-SCLC? #ELCC26 Early ...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination ...
DLL3: Does Target Expression Determine the Method of Targeting ...
Zocilurtatug Pelitecan Shows Clinical Benefit as a Potential First-in ...
DLL3-CD3药物原理 - 抖音
Molecular Partners to hold oral presentations on DLL3-targeting Radio ...
信达生物：DLL3/CD3双抗申报临床_手机新浪网
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung ...
速览！2026 CSCO 小细胞肺癌指南更新要点_腾讯新闻
华泰 | ASCO一线肺癌成焦点，国产新药有望重塑全球肿瘤治疗范式|肿瘤_新浪财经_新浪网
PHARMA JONPI .: TARLATAMAB TRAS SU RECIENTE APROBACIÓN EN EUROPA ...
復宏漢霖(02696)HLX3901注射液1期臨床研究於中國境內完成首例患者給藥
Rx Rundown: AbbVie, Novartis, MannKind and more
百利天恒的前世今生：朱义掌舵近三十年铸就创新药研发格局，核心产品营收占比近100%，多产品全球注册临床待启|净利润_新浪财经_新浪网
再鼎医药不到一个月大涨40%，Zoci或成基石药物_zoci_患者_全球
30년간 실패 거듭한 소세포폐암…전환점 마련한 '임델트라'[약전약후]
恒瑞医药：子公司收到4个药物临床试验批准通知书_恒瑞医药(600276)股吧_东方财富网股吧
